http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
한국에서 제1형 자가면역성 간염의 진단에 있어 International Autoimmune Hepatitis Group 점수 체계의 적정성
이상수,박영환,서동진,이한주,정영화,이영상,송희곤,정세라,표승일,송병철 대한간학회 2002 Clinical and Molecular Hepatology(대한간학회지) Vol.8 No.1
Background/Aims: There are no pathognomonic features of autoimmune hepatitis (AIH). Its diagnosis requires the exclusion of various other conditions. The aim of this study was to validate indirectly the International Autoimmune Hepatitis Group (IAHG) scoring system in diagnosing AIH. Methods: Twenty-six patients with Type 1 AIH and female patients with chronic hepatitis B (n=34), chronic hepatitis C (n=25), or toxic hepatitis (n=13) were evaluated according to 9 categories of pretreatment minimum required parameters proposed by IAHG. Aggregate scores of AIH to those of non-AIH groups, which were assessed before and after extracting the proportions of etiologic factors, were also compared and evaluated. Results: While aggregate scores of non-AIH groups, before extracting the proportions of etiologic factors, were 5.2±1.8, 5.6±1.1, and 7.4±1.2 in that order, those of AIH groups were 12.8±1.7. These were significantly higher than those of non-AIH groups (p$lt;0.01). All patients in AIH groups and only 1 patienta non-AIH group showed aggregate scores of more than 10. Aggregate scores after extracting the proportions of etiologic factors were more than 4 in all, except 2, patients. These should have been consistent with 10 if there were no etiologic factors in non-AIH groups. Conclusion: The IAHG scoring system might have a relatively excessive importance to the scores of categories excluding distinct etiologies from AIH. It might be difficult to differentiate AIH from chronic liver diseases of indistinct cause based on the IAHG scoring system.(Korean J Hepatol 2002;8:35-43)
( Sae Hwan Lee ),( Il Han Song ),( Ran Noh ),( Ha Yan Kang ),( Soon Young Ko ),( Eom Seok Lee ),( Seok Hyun Kim ),( An Na Kim ),( Byung Seok Lee ),( Hee Bok Chae ),( Hong Soo Kim ),( Young Woo Kang ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.1
Backgroud/Aims: Sorafenib, an oral multikinase inhibitor with antiangiogenic and antiproliferative properties, showed significant benefits in terms of time to progression and survival in patients with advanced hepatocellular carcinoma (HCC) in large clinical trials. The aim of this study was to investigate treatment outcomes of sorafenib in real clinical fields. Methods: From August 2007 to March 2012, patients with advanced HCC who received sorafenib in seven referral hospitals in Daejeon-Chungcheong province were retrospectively enrolled for the evaluation of tolerability, treatment response and survival following sorafenib administration. Treatment response was radiologically assessed by RECIST 1.1. Results: Among a total of 123 patients enrolled, sixty-eight (55%) patients received prior treatment and 74 (60%) patients had Child-Pugh A cirrhosis. One hundred-three (84%) patients were BCLC stage C; Ninety-three (76%) patients were modified UICC IV. The median duration of sorafenib treatment was 67 (14-452) days. Seventy-three (60%) patients have experienced adverse events, resulting in transient dose reduction or cessation. Treatment interruption was brought by disease progression (36%), adverse events (21%), hepatic failure (10%), and financial burden (7%). Complete response, partial response and stable disease were seen in none, 1% and 18%, respectively, and disease control rate was 29%. Median time to progression was 84 days and overall median survival was 139 days. Patients with decompensated cirrhosis showed a shorter median time to progression (61 vs. 104 days, p=0.036) and overall survival (63 vs. 168 days, p<0.001) compared to those with compensated cirrhosis. Child-Pugh class B/C (p=0.027) and prior treatment (p=0.015) were independent risk factors for survival. Conclusions: Clinical outcomes of sorafenib treatment in patients with advanced HCC were comparable to those of previous studies. The function of hepatic reserve and history of previous treatment were independent factors affecting survival.
포스터전시 : 만성 B형 간염의 클레부딘 초치료 중 내성이외의 원인에 의한 엔테카비어 교체 후 치료 효과 (초)
( In Do Song ),( Hyun Woong Lee ),( Hyung Joon Kim ),( Kwang Jin Kim ),( Kyu Hyun Yoon ),( Sang Pyo Han ),( Il Woon Park ),( Bong Ki Cha ),( Chang Hwan Choi ),( Jae Hyuk Do ),( Sae Kyung Chang ) 대한간학회 2010 Clinical and Molecular Hepatology(대한간학회지) Vol.16 No.3(S)
( Kyu Hyung Han ),( Seok Bae Kim ),( Il Han Song Sae Hwan Lee ),( Hong Soo Kim ),( Tae Hee Lee ),( Young Woo Kang ),( Seok Hyun Kim ),( Byung Seok Lee ),( Hee Bok Chae ),( Myung Joon Song ),( Ji Woong 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Sofosbuvir (SOF) and weight-based ribavirin (RBV) representd the only standard of care in hepatitis C virus (HCV) genotype 2 patients in Korea. Previous clinical trials showed about 90% sustained virological response at 12 weeks (SVR12). The purpose of this study is to reveal the real life experience of treatment and safety in Korean patients with HCV genotype 2 infection. Methods: We retrospectively analyzed the clinical data of chronic HCV genotype 2 patients treated with SOF + RBV from May 2016 to April 2017 at eight hospitals located in the Daejeon-Chungcheong area. Results: A total of 165 patients were treated with SOF + RBV. Of them, 107 patients who reached SVR12 were analyzed for treatment efficacy and safety. Mean age was 58.8±11.9 years (43-82) and 72 patients (67.3%) were female. 29 (27.1%) had cirrhotic change and 15 of them were treated for 16 weeks. SOF + RBV was the first-line treatment for 96 (89.7%) patients. Six (5.6%) and five (4.7%) patients were intolerant to interferon and relapsed after previous treatment that included interferon, respectively. During treatment, 10 patients (9.3%) experienced RBV reduction because of anemia. Adverse events such as dizziness, indigestion, itching, rash was found in 17 (15.9%) patients and no patient did not stop the treatment. HCV RNA was not detected after first 4 weeks in all patients and SVR12 was 100%. Conclusions: SOF + RBV treatment had excellent treatment efficacy and tolerable side effects for patients with HCV 2 infection in Korea.
( Byeong Wook Cho ),( Seok Bae Kim ),( Il Han Song ),( Sae Hwan Lee ),( Hong Soo Kim ),( Tae Hee Lee ),( Young Woo Kang ),( Seok Hyun Kim ),( Byung Seok Lee ),( Hee Bok Chae ) 대한간학회 2017 Clinical and Molecular Hepatology(대한간학회지) Vol.23 No.1
Background/Aims: The combination of daclatasvir (DCV) and asunaprevir (ASV) has demonstrated a high sustained virologic response at 12 weeks (SVR12) and a low rate of adverse events in previous clinical studies. The purpose of this study was to clarify the results of treatment and side effects in Korean patients with chronic hepatitis C virus (HCV) genotype Ib infection. Methods: We retrospectively analyzed clinical data from chronic HCV genotype Ib patients treated with DCV+ASV from August 2015 to September 2016 at five hospitals in the Daejeon-Chungcheong area. Results: A total of 152 patients were examined for resistance associated variants (RAVs). Among them, 15 (9.9%) were positive for Y93 and one (0.7%) was positive for L31. Of 126 patients treated with DCV+ASV, 83 patients completed treatment and 76 patients were included in safety and efficacy analysis. Five (6.6%) were positive for Y93 and 12 (15.8%) exhibited cirrhotic change. DCV+ASV was the first-line treatment for 58 (76.3%) patients. Eleven (14.5%) patients relapsed after previous treatment that included interferon and seven (9.2%) of these patients were found to be intolerant of interferon. Adverse events occurred in 10 (13.2%) patients and two patients stopped the medication because of severe itching and skin rash. SVR12 was 89.5% (68/76) in all patients and 91.5% (65/71) in RAV-negative patients. Conclusions: DCV+ASV showed good efficacy in patients with HCV Ib infection in Korea. Close monitoring is needed for severe adverse events and treatment failure, which were uncommon. (Clin Mol Hepatol 2017;23:51-56)
유전자형 1형과 2형의 한국인 만성 C형간염 환자에서 Glecaprevir/Pibrentasvir와 Sofosbuvir/Ledipasvir의 비교
신현덕 ( Hyun Deok Shin ),송일한 ( Il Han Song ),이세환 ( Sae Hwan Lee ),김홍수 ( Hong Soo Kim ),이태희 ( Tae Hee Lee ),은혁수 ( Hyuk Soo Eun ),김석현 ( Seok Hyun Kim ),이병석 ( Byung Seok Lee ),채희복 ( Hee Bok Chae ),김석환 ( Se 대한소화기학회 2024 대한소화기학회지 Vol.83 No.3
Background/Aims: This study compared the effectiveness and safety of glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/ledipasvir (SOF/LDV) in real-life clinical practice. Methods: The data from genotype 1 or 2 chronic hepatitis C patients treated with GLE/PIB or sofosbuvir + ribavirin or SOF/LDV in South Korea were collected retrospectively. The analysis included the treatment completion rate, sustained virologic response at 12 weeks (SVR12) test rate, treatment effectiveness, and adverse events. Results: Seven hundred and eighty-two patients with genotype 1 or 2 chronic hepatitis C who were treated with GLE/PIB (n=575) or SOF/LDV (n=207) were included in this retrospective study. The baseline demographic and clinical characteristics revealed significant statistical differences in age, genotype, ascites, liver cirrhosis, and hepatocellular carcinoma between the GLE/PIB and SOF/LDV groups. Twenty-two patients did not complete the treatment protocol. The treatment completion rate was high for both regimens without statistical significance (97.7% vs. 95.7%, p=0.08). The overall SVR12 of intention-to-treat analysis was 81.2% vs. 80.7% without statistical significance (p=0.87). The overall SVR12 of per protocol analysis was 98.7% vs. 100% without statistical significance (p=0.14). Six patients treated with GLE/PIB experienced treatment failure. They were all male, genotype 2, and showed a negative hepatitis C virus RNA level at the end of treatment. Two patients treated with GLE/PIB stopped medication because of fever and abdominal discomfort. Conclusions: Both regimens had similar treatment completion rates, effectiveness, and safety profiles. Therefore, the SOF/LDV regimen can also be considered a viable DAA for the treatment of patients with genotype 1 or 2 chronic hepatitis C. (Korean J Gastroenterol 2024;83:111-118)
( Young Min Kim ),( Suk Bae Kim ),( Il Han Song ),( Sae Hwan Lee ),( Hong Soo Kim ),( Tae Hee Lee ),( Young Woo Kang ),( Seok Hyun Kim ),( Byung Seok Lee ),( Hee Bok Chae ),( Myeong Jun Song ),( Ji Wo 대한간학회 2018 Clinical and Molecular Hepatology(대한간학회지) Vol.24 No.3
Background/Aims: Sofosbuvir plus ribavirin is a standard treatment for patients infected with chronic hepatitis C virus (HCV) genotype 2 in Korea. The purpose of this study was to examine the efficacy and safety of this treatment in Korean patients with chronic HCV genotype 2 infection. Methods: We retrospectively analyzed clinical data of patients treated with sofosbuvir plus ribavirin for chronic HCV genotype 2 from May 2016 to December 2017 at eight hospitals located in the Daejeon-Chungcheong area. Results: A total of 172 patients were treated with sofosbuvir plus ribavirin. Of them, 163 patients completed the treatment, and 162 patients were tested for sustained virologic response 12 weeks after treatment discontinuation (SVR12). Mean age was 59.6±12.3 years (27-96), and 105 (64.4%) patients were female. Of the total patients, 49 (30.1%) were diagnosed with cirrhosis, and 31 of them were treated for 16 weeks. Sofosbuvir plus ribavirin was the first-line treatment for 144 (88.3%) patients. Eleven (6.7%) patients were intolerant to previous interferon-based treatment. Eight (5.0%) patients relapsed after interferon-based treatment. HCV RNA non-detection rate at 4, 8, and 12 weeks was 97.5%, 99.1%, and 99.3%, respectively, and SVR12 was 98.8% (161/163). During treatment, 18 (11.0%) patients had to reduce their administrated dose of ribavirin because of anemia. One patient stopped the treatment because of severe anemia. Other adverse events, including dizziness, indigestion, and headache, were found in 26 (16.0%) patients. Conclusions: A 12-16 week treatment with sofosbuvir plus ribavirin is remarkably effective and well tolerated in Korean patients with chronic HCV genotype 2 infection. (Clin Mol Hepatol 2018;24:311-318)
김진호,박소연,김명환,박원철,이호정,이성구,주영민,서동완,송병철,민영일,유교상,고진규,한상택,정세라,주연호 대한소화기내시경학회 2000 Clinical Endoscopy Vol.20 No.2
An anomalous pancreaticobiliary ductal union is a rare anomaly occurring in the biliary tract. This anomaly has been implicated as a cause of choledochal cysts, bile duct and gallbladder carcinoma, and recurrent pancreatitis. A case is herein reported of a 63 year-old woman who suffered from gallbladder cancer associated with a choledochal cyst and an anomalous pancreaticobiliary union.